Evidence map›Paper›PMID 41319248›Full record

ArticleEmerging microbes & infections2025

Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice.

Lijun Ling, Luisa P Mori, Andrew Soper, Wenbo Yao, Andrew T McAuley, Ana R Leda, Rae Ann Spagnuolo, Nurjahan Begum, Martina Kovarova, Angela Wahl and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lijun LingDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Luisa P MoriThe Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, USA.
Andrew SoperInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Wenbo YaoInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew T McAuleyDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Ana R LedaDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Rae Ann SpagnuoloInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nurjahan BegumInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Martina KovarovaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Angela WahlDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Michael D CameronDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
Susana T ValenteThe Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, USA.
J Victor GarciaDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Mode of action of a new Tat HIV-1 inhibitorR01AI097012 · NIAID · UNIVERSITY OF FLORIDA · PI VALENTE, SUSANA T · 2012 to 2022
$7.5M
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque modelR01AI167732 · NIAID · UNIVERSITY OF FLORIDA · PI David T Evans, Susana T Valente · 2021 to 2026
$4.3M
Next generation ultra-long acting antiretroviral formulations for HIV treatment and preventionR01AI140799 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2018 to 2022
$3.9M
Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized miceR01AI177327 · NIAID · UNIVERSITY OF FLORIDA · PI J. Victor Garcia-Martinez, Susana T Valente · 2023 to 2026
$3.5M
Therapeutic Disruption of HIV Transcription by HIV-1 Tat Protein-Degrading MoleculesR01AI194820 · NIAID · UNIVERSITY OF FLORIDA · PI Susana T Valente · 2025 to 2026
$2.0M
NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI097012NIAID NIH HHS R01 AI140799NIAID NIH HHS R01 AI167732NIAID NIH HHS R01 AI177327NIAID NIH HHS R01 AI194820NIAID NIH HHS UM1 AI126619NIAID NIH HHS UM1 AI164559
6 · The paper itself

Abstract

Spironolactone (SP), a clinically used aldosterone antagonist, has been explored as an anti-HIV agent in models of HIV-1 latency for inducing transcriptional silencing of the viral reservoir

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsSpironolactoneAnimalsDisease Models, AnimalHumansMiceVirus LatencyVirus ReplicationAnti-HIV AgentsSpironolactoneChronic inflammationHIV-1 transcriptionhumanized mouse modellatency-promoting agentsSpironolactone

Identifiers

PMID41319248
PMCPMC12667289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.